Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–49. doi: 10.3322/caac.21660 SungH FerlayJ SiegelRL LaversanneM SoerjomataramI JemalA Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 209 49 10.3322/caac.21660 Open DOISearch in Google Scholar

2. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 358–76. doi: 10.1016/j.annonc.2022.12.013 HendriksLE KerrKM MenisJ MokTS NestleU PassaroA Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann Oncol 2023 34 358 76 10.1016/j.annonc.2022.12.013 Open DOISearch in Google Scholar

3. Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res 2020; 39: 204. doi: 10.1186/s13046-020-01709-5 JiangX WangJ DengX XiongF ZhangS GongZ The role of microenvironment in tumor angiogenesis J Exp Clin Cancer Res 2020 39 204 10.1186/s13046-020-01709-5 Open DOISearch in Google Scholar

4. Manzo A, Carillio G, Montanino A, Costanzo R, Sandomenico C, Rocco G, et al. Focus on nintedanib in NSCLC and other tumors. Front Med 2016; 3: 68. doi: 10.3389/fmed.2016.00068 ManzoA CarillioG MontaninoA CostanzoR SandomenicoC RoccoG Focus on nintedanib in NSCLC and other tumors Front Med 2016 3 68 10.3389/fmed.2016.00068 Open DOISearch in Google Scholar

5. Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J Pathol 2017; 241: 362–74. doi: 10.1002/path.4845 BridgemanVL VermeulenPB FooS BileczA DaleyF KostarasE Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models J Pathol 2017 241 362 74 10.1002/path.4845 Open DOISearch in Google Scholar

6. Wang Y, Yang R, Wang X, Ci H, Zhou L, Zhu B, et al. Evaluation of the correlation of vasculogenic mimicry, Notch4, DLL4, and KAI1/CD82 in the prediction of metastasis and prognosis in non-small cell lung cancer. Medicine 2018; 97: e13817. doi: 10.1097/MD.0000000000013817 WangY YangR WangX CiH ZhouL ZhuB Evaluation of the correlation of vasculogenic mimicry, Notch4, DLL4, and KAI1/CD82 in the prediction of metastasis and prognosis in non-small cell lung cancer Medicine 2018 97 e13817 10.1097/MD.0000000000013817 Open DOISearch in Google Scholar

7. Daum S, Hagen H, Naismith E, Wolf D, Pircher A. The role of anti-angiogenesis in the treatment landscape of non-small cell lung cancer - New combinational approaches and strategies of neovessel inhibition. Front Cell Dev Biol 2021; 8: 610903. doi: 10.3389/fcell.2020.610903 DaumS HagenH NaismithE WolfD PircherA. The role of anti-angiogenesis in the treatment landscape of non-small cell lung cancer - New combinational approaches and strategies of neovessel inhibition Front Cell Dev Biol 2021 8 610903 10.3389/fcell.2020.610903 Open DOISearch in Google Scholar

8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–50. doi: 10.1056/NEJMoa061884 SandlerA GrayR PerryMC BrahmerJ SchillerJH DowlatiA Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 2006 355 2542 50 10.1056/NEJMoa061884 Open DOISearch in Google Scholar

9. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al; LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143–55. doi: 10.1016/S1470-2045(13)70586-2 ReckM KaiserR MellemgaardA DouillardJY OrlovS KrzakowskiM LUME-Lung 1 Study Group Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Lancet Oncol 2014 15 143 55 10.1016/S1470-2045(13)70586-2 Open DOISearch in Google Scholar

10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47. doi: 10.1016/j.ejca.2008.10.026 EisenhauerEA TherasseP BogaertsJ SchwartzLH SargentD FordR New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 2009 45 228 47 10.1016/j.ejca.2008.10.026 Open DOISearch in Google Scholar

11. US National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (2009). [cited 2023 Apr 14]. Avaible at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm US National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0 2009 [cited 2023 Apr 14]. Avaible at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm Search in Google Scholar

12. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078–92. doi: 10.1056/NEJMoa1801005 GandhiL Rodríguez-AbreuD GadgeelS EstebanE FelipE De AngelisF Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer N Engl J Med 2018 378 2078 92 10.1056/NEJMoa1801005 Open DOISearch in Google Scholar

13. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami Net, al. IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018; 378: 2288–301. doi: 10.1056/NEJMoa1716948 SocinskiMA JotteRM CappuzzoF OrlandiF StroyakovskiyD NogamiN IMpower150 Study Group Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC N Engl J Med 2018 378 2288 301 10.1056/NEJMoa1716948 Open DOISearch in Google Scholar

14. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 924–37. doi: 10.1016/S1470-2045(19)30167-6 WestH McCleodM HusseinM MorabitoA RittmeyerA ConterHJ Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol 2019 20 924 37 10.1016/S1470-2045(19)30167-6 Open DOISearch in Google Scholar

15. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384: 665–73. doi: 10.1016/S0140-6736(14)60845-X GaronEB CiuleanuTE ArrietaO PrabhashK SyrigosKN GokselT Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Lancet 2014 384 665 73 10.1016/S0140-6736(14)60845-X Open DOISearch in Google Scholar

16. Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Heigener DF, Krzakowski M, et al. Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the Phase III LUME-Lung 1 Study. Target Oncol 2017; 12: 475–85. doi: 10.1007/s11523-017-0517-2 GottfriedM BennounaJ BondarenkoI DouillardJY HeigenerDF KrzakowskiM Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the Phase III LUME-Lung 1 Study Target Oncol 2017 12 475 85 10.1007/s11523-017-0517-2 Open DOISearch in Google Scholar

17. Metzenmacher M, Rizzo F, Kambartel K, Panse J, Schaufler D, Scheffler M, et al. Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. Future Oncol 2021; 17: 3965–76. doi: 10.2217/fon-2021-0424 MetzenmacherM RizzoF KambartelK PanseJ SchauflerD SchefflerM Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma Future Oncol 2021 17 3965 76 10.2217/fon-2021-0424 Open DOISearch in Google Scholar

18. Grohé C, Blau W, Gleiber W, Haas S, Hammerschmidt S, Krüger S, et al. Real-world efficacy of nintedanib plus docetaxel after progression on immune checkpoint inhibitors: Results from the ongoing, non-interventional VARGADO Study. Clin Oncol 2022; 34: 459–68. doi: 10.1016/j.clon.2021.12.010 GrohéC BlauW GleiberW HaasS HammerschmidtS KrügerS Real-world efficacy of nintedanib plus docetaxel after progression on immune checkpoint inhibitors: Results from the ongoing, non-interventional VARGADO Study Clin Oncol 2022 34 459 68 10.1016/j.clon.2021.12.010 Open DOISearch in Google Scholar

19. Corral J, Majem M, Rodríguez-Abreu D, Carcereny E, Cortes ÁA, Llorente M, et al. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. Clin Transl Oncol 2019; 21: 1270–9. doi: 10.1007/s12094-019-02053-7 CorralJ MajemM Rodríguez-AbreuD CarcerenyE CortesÁA LlorenteM Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program Clin Transl Oncol 2019 21 1270 9 10.1007/s12094-019-02053-7 Open DOISearch in Google Scholar

20. Riudavets M, Bosch-Barrera J, Cabezón-Gutiérrez L, Diz Taín P, Hernández A, Alonso M, et al. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Clin Transl Oncol 2021; 23: 2560–7. doi: 10.1007/s12094-021-02661-2 RiudavetsM Bosch-BarreraJ Cabezón-GutiérrezL Diz TaínP HernándezA AlonsoM Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma Clin Transl Oncol 2021 23 2560 7 10.1007/s12094-021-02661-2 Open DOISearch in Google Scholar

21. Hong SH, An HJ, Kim K, Lee SS, Lee YG, Yuh YJ, et al. Impact of epidermal growth factor receptor mutation on clinical outcomes of nintedanib plus docetaxel in patients with previously treated non-small cell lung cancer from the Korean Named Patient Program. Oncology 2019; 96: 51–8. doi: 10.1159/000492472 HongSH AnHJ KimK LeeSS LeeYG YuhYJ Impact of epidermal growth factor receptor mutation on clinical outcomes of nintedanib plus docetaxel in patients with previously treated non-small cell lung cancer from the Korean Named Patient Program Oncology 2019 96 51 8 10.1159/000492472 Open DOISearch in Google Scholar

22. Dienstmann R, Braña I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 2011; 16: 1729–40. doi: 10.1634/theoncologist.2011-0163 DienstmannR BrañaI RodonJ TaberneroJ. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs Oncologist 2011 16 1729 40 10.1634/theoncologist.2011-0163 Open DOISearch in Google Scholar

23. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010; 28: 949–54. doi: 10.1200/JCO.2009 DahlbergSE SandlerAB BrahmerJR SchillerJH JohnsonDH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J Clin Oncol 2010 28 949 54 10.1200/JCO.2009 Open DOISearch in Google Scholar